Wednesday, November 26, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

TG Therapeutics Short Interest Declines Indicating Potential Shift in Market Sentiment

Elaine Mendonca by Elaine Mendonca
January 19, 2024
in Breaking News
0
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

TG Therapeutics (NYSE:TGTX) has experienced a notable decline in its short interest, with the percentage of float falling by 12.86% since the previous report. As of January 19, 2024, the company reported 31.83 million shares sold short, which accounts for 25.88% of all regular shares available for trading. This suggests that traders are exhibiting less bearishness towards the stock. The current short interest ratio stands at 5.0, indicating a moderate level of pessimism.

Understanding short interest is crucial as it provides insights into market sentiment surrounding a specific stock. An increase in short interest typically signifies bearishness, while a decrease can indicate bullishness. Nevertheless, it is important to note that a decline in short interest does not guarantee an immediate rise in the stock’s value.

When comparing TG Therapeutics’s short interest to its peers, the company’s average short interest as a percentage of float is reported to be 15.13% by Benzinga Pro.

In conclusion, the decrease in TG Therapeutics’s short interest may suggest a shift in market sentiment towards the stock. However, it is crucial to consider other factors before making any investment decisions.

TG Therapeutics Inc. (TGTX) Sees Mixed Performance on January 19, 2024

TG Therapeutics Inc. (TGTX) experienced a mixed performance on January 19, 2024. The price of TGTX shares decreased by $0.07, marking a 0.46% drop from the previous market close. The stock closed at $15.07 but saw a slight increase of $0.03 in after-hours trading.

TGTX’s current trading position near the lower end of its 52-week range suggests that investors may perceive the stock as undervalued. However, it is important to note that the stock’s performance should be evaluated in conjunction with other fundamental and technical indicators to gain a comprehensive understanding of its investment potential.

Additionally, the fact that TGTX is trading below its 200-day simple moving average indicates a potential bearish sentiment in the market. When a stock is trading below this moving average, it suggests that the overall trend may be downward.

It is worth mentioning that the price change of $0.03 in after-hours trading may not have a significant impact on the overall performance of TGTX. After-hours trading refers to the buying and selling of stocks outside the regular trading hours of the stock market. The volume and liquidity during this period are typically lower compared to regular market hours, which can result in more volatile price movements.

Investors should closely monitor TGTX’s performance in the coming days to determine whether the recent price drop and subsequent after-hours increase are indicative of a trend reversal or merely short-term fluctuations. Conducting thorough research, considering the company’s financials, and consulting with a financial advisor can help investors make informed decisions regarding TGTX and their investment strategies.

TG Therapeutics Inc. (TGTX) Shows Mixed Performance with Significant Revenue Changes: A Path Towards Profitability

TG Therapeutics Inc. (TGTX) has shown mixed performance in its stock prices on January 19, 2024. The company’s total revenue has experienced significant changes over the past year and quarter. TGTX reported a total revenue of $2.79 million over the past year, representing a 58.36% decrease compared to the previous year. However, the company’s total revenue experienced a substantial 931.57% increase since the last quarter, reaching $165.81 million. TGTX reported a net loss of -$198.34 million over the past year, but the net income has increased by 43.02% compared to the previous year. In the third quarter of 2023, TGTX reported a net income of $113.93 million, indicating a remarkable 339.3% increase since the previous quarter. TGTX reported an EPS of -$1.46 over the past year, representing a loss per share. However, the company has improved its EPS by 44.37% compared to the previous year. In the third quarter of 2023, TGTX reported an EPS of $0.73, indicating a significant increase of 317.21% since the previous quarter. These positive trends suggest that TGTX has made significant strides in improving its financial performance and may be on a path towards profitability.

Tags: TGTX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Technology Robotics Trading online

Datasea Inc Implements Reverse Stock Split to Meet Nasdaq Listing Requirements

MMM stock news

Resumption of Trading for Arena Group Holdings Shares

Alternative Energy Markets and money (1)

Options Market Activity for Diamondback Energy Bullish vs Bearish Sentiment

Recommended

TG Therapeutics Short Interest Declines Indicating Potential Shift in Market Sentiment

2 years ago
Freedom Stock

BlackRock’s $89 Million Bet on Freedom: A Vote of Confidence or a Risky Gamble?

2 months ago
Uranium Energy Stock

Uranium Energy Shares Experience Sharp Price Decline Amid Broader Optimism

1 week ago
Plug Power Stock

Plug Power Shares Show Signs of Life After Steep Decline

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Dow Jones Surges as AI Stocks Rebound and Rate Cut Hopes Build

Riding the AI Investment Wave: The iShares Robotics and AI ETF

A Strategic Shift for MP Materials: US-Saudi Partnership Challenges China’s Rare Earth Dominance

Nike Shares: Institutional Investors Bet Against the Downtrend

Energy Fuels Stock: Insider Selling Raises Concerns

Microsoft’s Strategic Overhaul: A Bold Response to Market Pressures

Trending

Replimune Stock
Analysis

Biotech Battle Royale: Replimune’s High-Stakes Market Clash

by Felix Baarz
November 26, 2025
0

A dramatic financial confrontation is unfolding around Replimune Group, where hedge funds betting against the company face...

Kraft Heinz Stock

Kraft Heinz Dividend: A High-Yield Trap for Investors?

November 26, 2025
Nio Stock

Nio’s Paradox: Strong Quarterly Results Overshadowed by Cautious Outlook

November 26, 2025
Dow Jones Stock

Dow Jones Surges as AI Stocks Rebound and Rate Cut Hopes Build

November 26, 2025
iShares Robotics and Artificial Intelligence Stock

Riding the AI Investment Wave: The iShares Robotics and AI ETF

November 26, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Biotech Battle Royale: Replimune’s High-Stakes Market Clash
  • Kraft Heinz Dividend: A High-Yield Trap for Investors?
  • Nio’s Paradox: Strong Quarterly Results Overshadowed by Cautious Outlook

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com